About: Artemisia annua: Trials are needed for COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Artemisia annua: Trials are needed for COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Artemisia annua: Trials are needed for COVID‐19
Creator	Ahmad, \| Shah, Ali Ahmad, Iftekhar Haq, Faiz Rahman, Ur Roman, Muhammad Saeed, \| Suleman, Naveed Syed Murtaza, \| Ullah, Sami Ullah, Wajahat
Source	Medline; PMC
abstract	In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS‐CoV‐2 and disease called COVID‐19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS‐CoV‐2. COVID‐19 is great challenge for scientist across the globe. Bioactive compound present in Artemisia annua against, hepatitis B virus, bovine viral diarrhea virus, and Epstein–Barr virus. A. annua have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS‐CoV‐2. Scientific attention is needed toward this agent to address for the treatment of COVID‐19.
has issue date	2020-05-27(xsd:dateTime)
bibo:doi	10.1002/ptr.6733
bibo:pmid	32424845
has license	no-cc
sha1sum (hex)	6989c9e2091f0dc5628a2bd9d07e1af183318c8f
schema:url	https://doi.org/10.1002/ptr.6733
resource representing a document's title	Artemisia annua: Trials are needed for COVID‐19
has PubMed Central identifier	PMC7276816
has PubMed identifier	32424845
schema:publication	Phytother Res
resource representing a document's body	covid:6989c9e2091f0dc5628a2bd9d07e1af183318c8f#body_text
is schema:about of	named entity 'COVID-19' named entity 'Islam' named entity 'accounting' named entity 'China' named entity 'COVID' named entity 'sterols' named entity 'virus' named entity 'antiviral agent' named entity 'traditional Chinese medicine' named entity 'conventional medicine' named entity 'antiviral therapies' named entity 'artemisinin' named entity 'Emami' named entity 'prophylaxis' named entity 'SARS-CoV' named entity 'Yang' named entity 'bioactive compound' named entity 'symptom' named entity 'virus' named entity 'antimalarial drugs' named entity 'malaria' named entity 'Artemisinin' named entity 'antiviral activity' named entity 'Jain' named entity 'Artemisia annua' named entity 'Herpes Simplex virus type 1' named entity 'SARS' named entity 'traditional herbal medicine' named entity 'natural products' named entity 'China' named entity 'antiviral' named entity 'Yang' named entity 'infectious diseases' named entity 'acyclovir' named entity 'COVID-19' named entity 'Artemisia' named entity 'ARTEMISIA ANNUA' named entity 'COVID-19' named entity 'NEEDED'
is part of of	Artemisia annua: Trials are needed for COVID‐19 covid:6989c9e2091f0dc5628a2bd9d07e1af183318c8f#body_text In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS‐CoV‐2 and disease called COVID‐19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS‐CoV‐2. COVID‐19 is great challenge for scientist across the globe. Bioactive compound present in Artemisia annua against, hepatitis B virus, bovine viral diarrhea virus, and Epstein–Barr virus. A. annua have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS‐CoV‐2. Scientific attention is needed toward this agent to address for the treatment of COVID‐19.

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software